Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a ...

The endoscopic device manufactured by Maquet was originally developed for harvesting of the saphenous vein and radial artery as conduits for coronary artery bypass graft surgery. These vessels are ...